Abstract:Objective To evaluate the reporting quality of randomized controlled trials (RCT) on the treatment of rectal prolapse by Xiaozhiling Injection. Methods The RCTs of Xiaozhiling Injection in the treatment of rectal prolapse were systematically searched by PubMed, Cochrane Library, CNKI, VIP, Wanfang dara and CBM from the database establishment to July 2021, and the included literature was evaluated by CONSORT statement (2010 edition). Results A total of 18 articles were included. Among them, 8 articles (44%) described the purpose or hypothesis of the study, 5 articles (28%) reported the method of generating random sequence, 1 articles (6%) gave the type of random method, 1 articles (6%) mentioned the allocation hidden mechanism, 8 articles (44%) referred to adverse events, and 2 articles (11%) described the limitations of the study. The writing of the topic was not in accordance with the standard, and blind method was not applied in all the literature, and there was a lack of description of the trial design, sample size estimation, auxiliary analysis, extensibility, trial registration, funding, and other aspects. Conclusion There are some deficiencies in the report quality of Xiaozhiling Injection in the treatment of rectal prolapse RCTs. It is suggested that the researchers refer to CONSORT statement to design, implement and write RCT, so as to improve the research quality.
李莹倩 包文亮 李华山. 基于CONSORT声明评价消痔灵注射液治疗直肠脱垂随机对照试验的报告质量[J]. 中国医药导报, 2022, 19(5): 133-137.
LI Yingqian BAO Wenliang LI Huashan. Reporting quality of randomized controlled trials of Xiaozhiling Injection for rectal prolapse based on CONSORT statement#br#. 中国医药导报, 2022, 19(5): 133-137.